| [1] |
Schulte KM, Talat N. Castleman's disease--a two compartment model of HHV8 infection. Nat Rev Clin Oncol 2010; 7:533-543.
doi: 10.1038/nrclinonc.2010.103 |
| [2] |
Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956; 9:822-830.
doi: 10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4 pmid: 13356266 |
| [3] |
Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood 2020; 135:1353-1364.
doi: 10.1182/blood.2019000931 pmid: 32106302 |
| [4] |
Carbone A, Borok M, Damania B, Gloghini A, Polizzotto MN, Jayanthan RK, et al. Castleman disease. Nat Rev Dis Primers 2021; 7:84.
doi: 10.1038/s41572-021-00317-7 pmid: 34824298 |
| [5] | Huang Z, Jin T, Zhang X, Wu Z. Pancreatic mass found to be Castleman disease, a rare case report. Asian J Surg 2020; 43:767-768. |
| [6] | Pai SA, Naresh KN, Borges AM. Report of a case with clinical and pathologic features of castleman disease that predates Castleman's report by more than 50 years. Arch Pathol Lab Med 2022; 146:1412-1415. |
| [7] |
Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972; 29:670-683.
doi: 10.1002/1097-0142(197203)29:3<670::aid-cncr2820290321>3.0.co;2-# pmid: 4551306 |
| [8] | Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 2015; 56:1252-1260. |
| [9] |
Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 2017; 129:1646-1657.
doi: 10.1182/blood-2016-10-746933 pmid: 28087540 |
| [10] |
Altinbas NK, Gundogdu Anamurluoglu E, Oz II, Yuce C, Yagci C, Ustuner E, et al. Real-time sonoelastography of parotid gland tumors. J Ultrasound Med 2017; 36:77-87.
doi: 10.7863/ultra.16.02038 pmid: 27925646 |
| [11] | Angang D, Jia L, Xia G, Ping X, Jiang L. Gray scale and doppler ultrasonography features of the carcinoma ex pleomorphic adenoma. Dentomaxillofac Radiol 2018; 47:20170268. |
| [12] |
Wang CW, Chu YH, Chiu DY, Shin N, Hsu HH, Lee JC, et al. JOURNAL CLUB: the warthin tumor score: a simple and reliable method to distinguish warthin tumors from pleomorphic adenomas and carcinomas. AJR Am J Roentgenol 2018; 210:1330-1337.
doi: 10.2214/AJR.17.18492 |
| [13] | Quer M, Hernandez-Prera JC, Silver CE, Casasayas M, Simo R, Vander Poorten V, et al. Current trends and controversies in the management of warthin tumor of the parotid gland. Diagnostics (Basel) 2021; 11:1467. |
| [14] |
Tretiakow D, Stodulski D, Skorek A. Regarding the concurrent presence of secretory carcinoma and Warthin's tumor in the ipsilateral parotid gland. Oral Oncol 2020; 109:104763.
doi: 10.1016/j.oraloncology.2020.104763 |
| [15] |
Jechova A, Kuchar M, Novak S, Koucky V, Dostalova L, Zabrodsky M, et al. The role of fine-needle aspiration biopsy (FNAB) in Warthin tumour diagnosis and management. Eur Arch Otorhinolaryngol 2019; 276:2941-2946.
doi: 10.1007/s00405-019-05566-7 pmid: 31321502 |
| No related articles found! |
|
||